Federal contract award
75A50123F33006
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | 75A50120D00017 |
| Set-aside | Not reported |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $330.2M |
| Current contract value | $330.2M |
| Potential contract value / ceiling | $330.2M |
| Start date | Aug 22, 2023 |
| Current end date | Apr 11, 2025 |
| Potential end date | Apr 11, 2025 |
| Latest award activity | Dec 11, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 8 of 8 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Dec 11, 2025 | P00007 | $0 | CLINICAL TRIAL PLANNING AND EXECUTION - COVID NEXT GENERATION VACCINE |
| Apr 11, 2025 | P00006 | $0 | EOI::EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING::EOI NOTIFICATION OF TERMINATION FOR CONVENIENCE (COMPLETE) |
| Oct 31, 2024 | P00005 | $0 | CLINICAL TRIAL PLANNING AND EXECUTION - COVID NEXT GENERATION VACCINE |
| Sep 25, 2024 | P00004 | $2.7M | CLINICAL TRIAL PLANNING AND EXECUTION - COVID NEXT GENERATION VACCINE |
| May 17, 2024 | P00003 | $0 | CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION |
| May 6, 2024 | P00002 | $0 | CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION |
| Oct 27, 2023 | P00001 | $0 | CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION |
| Aug 22, 2023 | 0 | $327.6M | CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.